简单地概述了CROWN研究的最新结果,该研究比较了洛拉提尼布与crizotinib在患有晚期非小细胞肺癌的人群中的结果

相关实验视频

Updated: Jul 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Benjamin J Solomon¹, Todd M Bauer², Tony S K Mok³

¹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Future oncology (London, England)

|June 12, 2023

概括

更新的CROWN研究结果显示,与crizotinib相比,lorlatinib在晚期形淋巴瘤激酶阳性非小细胞肺癌中提供了优越的长期益处.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

这项CROWN研究调查了与形淋巴瘤激酶 (ALK) 基因改变的高级非小细胞肺癌 (NSCLC) 的治疗方法.
之前的研究已经确定了lorlatinib和crizotinib作为ALK阳性NSCLC的治疗选择.

研究的目的:

介绍CROWN研究的最新3年结果,比较lorlatinib与crizotinib在先前未接受治疗的晚期ALK阳性NSCLC患者中的疗效和安全性.
与crizotinib相比,评估洛拉提尼布的持续益处和长期结果.

主要方法:

皇冠研究是一项正在进行的研究试验,比较了晚期NSCLC和ALK变异患者的洛拉提尼布和克里佐提尼布.
分析了经过3年的观察后更新的数据,以比较治疗结果.

主要成果:

3年后,64%的洛拉提尼布患者在没有癌症进展的情况下活着,而克里佐替尼布的患者只有19%.
与crizotinib相比,洛拉提尼布表明癌症向大脑扩散的减少.
虽然洛拉提尼布的副作用更严重,但它们是可控的;然而,危及生命的副作用发生在13%的洛拉提尼布患者中,而克里佐替尼布患者中只有8%.

结论:

与crizotinib相比,3年后,洛拉提尼布在晚期ALK阳性NSCLC患者中提供了显著更大和更持久的临床益处.
尽管副作用可以控制,但接受洛拉提尼布的患者需要仔细监测.
这些发现支持洛拉提尼布作为这种患者群体首选的第一线治疗选择.

关键词:

皇冠皇冠皇冠简单的语言简要概要.洛拉提尼布 (lorlatinib) 是一种药物.其他非小细胞肺癌.

相关概念视频

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

02:57

Targeted Cancer Therapies

7.7K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.7K

02:39

lncRNA - Long Non-coding RNAs

8.7K

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

8.7K

01:11

Clinical Trials: Overview

3.0K

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...